It is one of the largest series A yet for a Cambridge spin-out.
DefiniGen, a biotech specialising in stem cell manufacturing has closed its series A with £2.3m ($3.85m). Investors in the Cambridge University spin-out include Cambridge Enterprise and 24 Haymarket, which co-led both halves of the series, Jonathan Milner, CEO of Abcam, Providence Investment Company and Cambridge Capital Group. They are joined by London Business Angels, Wren Capital and Ranworth Capital.
The company, launched less than two years ago, is carefully considering a move into regenerative medicine. It will spend the next…
